 Shares of Atai Life Sciences, backed by billionaire investor Peter Thiel, surged 40 percent in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of 3.19 billion. The Berlin-based biotech startup, which is exploring the use of psychedelic treatments for mental illnesses, raised 225 million from selling 15 million shares in. 